Clinical Trials Logo

Healthy Controls clinical trials

View clinical trials related to Healthy Controls.

Filter by:

NCT ID: NCT03715972 Completed - Sickle Cell Disease Clinical Trials

Cerebrovascular Reserve and White Matter Disease in Patients With Chronic Anemia

CVR
Start date: July 15, 2018
Phase:
Study type: Observational

This is primarily an observational trial in patients with chronic anemia syndromes (sickle cell disease and thalassemia) and control subjects. The key purpose is to understand how brain blood flow reserve (the ability of the brain to increase its flow in response to stress) is altered in patients with chronic anemia. Since this parameter may depend on anemia severity, we will perform the MRI monitoring prior to and following clinically indicated transfusions in a subset of patients. Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose. The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients as well as 40 control subjects recruited from first degree relatives of the sickle cell disease population. All eligible subjects will be asked to provide informed consent before participating in the study.

NCT ID: NCT03649555 Active, not recruiting - Healthy Controls Clinical Trials

Reliability of [18F]-FTC-146 Brain Uptake in Healthy Controls

rSIG
Start date: February 1, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to understand the reliability of [18F]-FTC-146 brain uptake in healthy controls.

NCT ID: NCT03520543 Completed - Healthy Controls Clinical Trials

[11C]Yohimbine PET Study of alpha2-AR

[11C]Yohimbine
Start date: May 21, 2018
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to model tissue specific kinetics of [11C]Yohimbine in healthy male participants by positron emission tomography (PET) and the appropriate arterial input function (part A) ; to determine the reproducibility of measures (classical test-retest study, part B1) and to measure the blocking of [11C]Yohimbine uptake in the brain following single oral dose administration of clonidine (part B2).

NCT ID: NCT03513835 Completed - Healthy Controls Clinical Trials

Diagnostic Screening Tests and Potential Biomarkers in Mitochondrial Myopathies

Start date: January 1, 2018
Phase:
Study type: Observational

The purpose of this study is to develop simple diagnostic screeningtests and investigate potential biomarkers for identifying patients with abnormalities of mitochondrial function, which also can be used as outcome measures in future clinical trials. The study will investigate two submaximal tests: a submaximal handgrip test and a walking test. Furthermore investigators will investigate Acyl-carnitine profiles and GDF-15 levels in patients with mitochondrial myopathy.

NCT ID: NCT03495869 Completed - Opioid-use Disorder Clinical Trials

Feasibility and Validation of a Standard Phenotyping Assessment Battery

PhAB
Start date: June 21, 2018
Phase:
Study type: Observational

The overall goal of this project is to collect preliminary data on psychosocial measures and behavioral performance comparing individuals with Opioid Use Disorder, Cocaine Use Disorder, dual diagnosis of Opioid and Cocaine Use Disorder, and Healthy Controls in an effort to determine overall feasibility of a phenotypic "fingerprint" for cohorts of individuals with addictions for use during clinical trials.

NCT ID: NCT03397108 Active, not recruiting - Ulcerative Colitis Clinical Trials

Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease

Start date: July 4, 2017
Phase:
Study type: Observational

Breastfeeding is beneficial to both mother and baby. However, many breastfeeding women are affected by long-term health conditions and need to take medications. Sometimes, concerns about transfer of drugs to infants via breast milk lead the mothers to either avoid breastfeeding or stop their medication. Inflammatory Bowel Disease (IBD) is a chronic condition that is marked by an abnormal response of the body's immune system, and high levels of certain proteins that cause inflammation (Cytokines like Tumor Necrosis Factor-alpha or TNFα). A group of drugs called "biologics" target and stop these proteins from causing inflammation, and have been successfully used to treat this condition. Inflammatory proteins may be present in breast milk of healthy women in variable levels, and may play a role in development of infant's brain and immune system. This study is being conducted to investigate: - Concentration of some of the inflammatory proteins in breast milk of mothers with IBD and healthy controls - Interaction between these proteins and biologics in breast milk of women with IBD - Potential role of these proteins (and their interaction with biologics) on development of infant learning and memory function It has been presumed that concentrations of TNFα and some other cytokines are higher in breast milk of women with IBD, and the biologics can normalize these high levels. Due to precautions for COVID-19, the study now consists of only two mandatory study visits and two optional study visits. The mandatory visits include two home visits in the first 4 months postpartum to complete a participant questionnaire and collect a small sample of breast milk at each visit. The optional study visits consist of two visits at the Hospital for Sick Children for evaluation of learning and memory function of the infant at the ages of 12 and 18 months. Additionally, mothers will be required to complete for their infant subscales of The Ages and Stages Questionnaires®, Third Edition (ASQ®-3) either in person or over the telephone at the ages of 12 months and 18 months.

NCT ID: NCT03249233 Recruiting - Keratoconus Clinical Trials

Corneal Thickness Changes With Scleral Contact Lenses

Start date: June 22, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate changes in the corneal thickness of scleral contact lens wearers in a keratoconic (KC) population and compare to age-matched controls. The hypothesis is that scleral contact lens wear is associated with low levels of corneal hypoxia including measurable changes in corneal thickness. Corneal thickness will be altered post scleral lens wear compared to pre-lens wear and the amount of alteration will correlate to the fitting characteristics in the central zone of the scleral lenses. We propose to take a sample of keratoconic and control participants, fit them in scleral lenses, and to measure topographic corneal thickness after 8-10 hours of scleral lens wear after three weeks of wear, to compare two instruments in the measurement of corneal thickness, and to compare the effects of varying central corneal clearance of the scleral lens on corneal thickness.

NCT ID: NCT03206463 Terminated - Bipolar Disorder Clinical Trials

Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

THC-BD
Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the acute cognitive and psychophysiological effects of the main psychoactive constituent of cannabis, 9-delta-tetrahydrocannabinol (THC) in individuals with euthymic bipolar disorder (BD), and to begin probing the mechanisms that may underlie its effects in this illness. This study is expected to contribute to a better characterization of specific effects of THC in individuals with BD compared to healthy controls (HC).

NCT ID: NCT03176745 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Number of Multiple Breath Washout Tests in Adults With Pulmonary Disease and Healthy Controls

Start date: July 1, 2015
Phase: N/A
Study type: Observational

The investigators aim to determine the optimal number of measurements required for multiple-breath-washout derived lung function parameters in adults with pulmonary disease as well as in healthy controls

NCT ID: NCT03162185 Recruiting - Healthy Controls Clinical Trials

Serotonin and Motor Plasticity

Start date: April 1, 2017
Phase: Phase 4
Study type: Interventional

With this study, the investigators aim to test whether acute administration of selective serotonin reuptake inhibitors (SSRI) improves motor performance in a sequential motor learning task in comparison to placebo in healthy humans.